Business Context and Reporting Period
This Form 8-K Current Report was filed by Mangoceuticals, Inc. (MGRX) on October 2, 2024, covering events occurring between August 15, 2024, and October 2, 2024. The Company, incorporated in Texas and listed on the Nasdaq Capital Market, is an emerging growth company. The filing primarily details unregistered sales of equity securities, including stock issuances for consulting and marketing services, advances under an Equity Line of Credit (ELOC), and conversions of preferred stock.
Key Financial Metrics and Transactions
The filing does not provide consolidated revenue, profit, cash flow, or margin data for a specific reporting period. Instead, it details specific capital-raising and compensation transactions:
- Consulting and Marketing Stock Issuances:
- August 15, 2024: Issued 150,000 shares to Veritas Consulting Group valued at $43,155 ($0.2877/share) plus $7,500/month cash.
- August 22, 2024: Issued 195,000 shares to Levo Healthcare Consulting valued at $56,102 ($0.2877/share) plus $6,250/month cash. Includes milestone warrants for up to 300,000 shares.
- September 10, 2024: Issued 650,000 shares to Luca Consulting, LLC valued at $175,500 ($0.27/share) plus $30,000 cash.
- Equity Line of Credit (ELOC):
- October 1, 2024: Sold 2,000,000 shares to Platinum Point Capital at $0.26/share, netting $521,016 after fees.
- Preferred Stock Conversions:
- September 26, 2024: Converted 140 shares of Series B Preferred Stock into 718,552 common shares (valued at $154,000).
- October 2, 2024: Converted 190 shares of Series B Preferred Stock into 1,003,842 common shares (valued at $209,000).
Material Changes Versus Prior Period
The filing does not provide comparative financial statements or metrics against a prior period. The material changes disclosed are the execution of new service agreements involving equity compensation and the utilization of the ELOC facility established in April 2024. The issuance of approximately 1.9 million shares for services and 2 million shares via the ELOC represents a significant increase in outstanding share count during this window.
Guidance, Outlook, and Risks
Management Commentary and Milestones: The Company has established performance milestones with Levo Healthcare Consulting, including the potential issuance of warrants for up to 300,000 shares upon reaching customer counts of 1,000, 2,500, 5,000, and 10,000. The ELOC allows for up to $25 million in future capital raises, subject to trading volume limits.
Risks and Contingencies:
- Dilution: Significant share issuances for services and debt conversion increase the risk of shareholder dilution.
- Liquidity Dependence: The Company relies on the ELOC for liquidity, which is subject to market trading volume constraints (100% of average daily volume over five days).
- Contractual Obligations: The Company has committed to monthly cash payments for consulting services alongside equity grants.
Investor Verification Checklist
- Verify the total number of shares issued for services (1,000,000 shares) and the ELOC (2,000,000 shares) against the current authorized share count to assess dilution impact.
- Confirm the status of the ELOC commitment period and the remaining available capacity under the $25 million facility.
- Review the vesting schedule for the 195,000 shares issued to Levo Healthcare Consulting and the specific criteria for the 300,000 warrant shares.
- Check the Company's cash position to ensure it can meet the monthly cash obligations ($7,500 to Veritas, $6,250 to Levo, and $5,000/month to Luca) alongside operational expenses.
- Validate the conversion ratios and pricing for the Series B Preferred Stock conversions to ensure alignment with the original terms.